TCG Crossover Management, LLC - MOONLAKE IMMUNOTHERAPEUTICS ownership

MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 24 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
TCG Crossover Management, LLC ownership history of MOONLAKE IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q4 2022$10,500,000
+35.3%
1,000,0000.0%1.85%
-20.4%
Q3 2022$7,760,000
+47.8%
1,000,0000.0%2.33%
+4.4%
Q2 2022$5,250,0001,000,0002.23%
Other shareholders
MOONLAKE IMMUNOTHERAPEUTICS shareholders Q2 2022
NameSharesValueWeighting ↓
BVF INC/IL 21,751,284$465,259,96517.01%
Cormorant Asset Management, LP 6,892,101$147,4229.71%
HighVista Strategies LLC 122,201$2,613,8792.13%
Ally Bridge Group (NY) LLC 72,850$1,558,2622.04%
Ghost Tree Capital, LLC 195,000$4,171,0001.23%
GREAT POINT PARTNERS LLC 278,334$5,953,5641.17%
SILVERARC CAPITAL MANAGEMENT, LLC 105,750$2,261,9930.93%
SVB FINANCIAL GROUP 16,173$345,9400.66%
Velan Capital Investment Management LP 23,400$500,5260.43%
BOULDER HILL CAPITAL MANAGEMENT LP 14,500$310,1550.25%
View complete list of MOONLAKE IMMUNOTHERAPEUTICS shareholders